T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease

[1] Patch C(2011)Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study Am J Kidney Dis 57 856-862

[2] Charlton J(2013)Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany Nephrol Dial Transplant 28 1472-1487

[3] Roderick PJ(2007)Autosomal dominant polycystic kidney disease Lancet 369 1287-1301

[4] Gulliford MC(2006)Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes Clin J Am Soc Nephrol 1 148-157

[5] Neumann HP(2010)Imaging for the prognosis of autosomal dominant polycystic kidney disease Nat Rev Nephrol 6 96-106

[6] Jilg C(2012)Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 7 479-486

[7] Bacher J(2009)MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement Clin J Am Soc Nephrol 4 719-725

[8] Nabulsi Z(2007)European Society of Urogenital Radiology (ESUR). ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis Eur Radiol 17 2692-2696

[9] Malinoc A(2009)Current status of gadolinium toxicity in patients with kidney disease Clin J Am Soc Nephrol 4 461-469

[10] Hummel B(1997)Single-shot T2-weighted MR imaging of the upper abdomen: preliminary experience with double-echo HASTE technique AJR Am J Roentgenol 169 1291-1293

[1] Patch C(2011)Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study Am J Kidney Dis 57 856-862

[2] Charlton J(2013)Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany Nephrol Dial Transplant 28 1472-1487

[3] Roderick PJ(2007)Autosomal dominant polycystic kidney disease Lancet 369 1287-1301

[4] Gulliford MC(2006)Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes Clin J Am Soc Nephrol 1 148-157

[5] Neumann HP(2010)Imaging for the prognosis of autosomal dominant polycystic kidney disease Nat Rev Nephrol 6 96-106

[6] Jilg C(2012)Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 7 479-486

[7] Bacher J(2009)MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement Clin J Am Soc Nephrol 4 719-725

[8] Nabulsi Z(2007)European Society of Urogenital Radiology (ESUR). ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis Eur Radiol 17 2692-2696

[9] Malinoc A(2009)Current status of gadolinium toxicity in patients with kidney disease Clin J Am Soc Nephrol 4 461-469

[10] Hummel B(1997)Single-shot T2-weighted MR imaging of the upper abdomen: preliminary experience with double-echo HASTE technique AJR Am J Roentgenol 169 1291-1293